subscribe
 

Biotech firm expands technical ops

4th December 2017


Orchard Therapeutics, a clinical-stage biotechnology company dedicated to transforming the lives of patients with rare disorders through innovative gene therapies, has announced the opening of a second facility for technical operations in the San Francisco Bay Area of California, USA.

In combination with the existing Foster City site, the new facility quadruples Orchard¹s laboratory footprint for the technical operations that support development and validation of processes and controls for the manufacture of the company's ex-vivo lentiviral gene therapy products.

Stewart Craig, chief manufacturing officer of Orchard, said, "Since the start of its technical operations in April 2016, Orchard has made progress in building a world-class team of experts for the development, manufacture and delivery of our ex-vivo gene therapy product pipeline. Opening of the new Menlo Park facility represents the next step of a phased plan to establish a fully integrated infrastructure for the company's technical opertaions. Even as we open the new Menlo Park site, we are already evaluating sites for a further custom-built facility in the Bay area to provide another threefold increase in our overall capacity with additional operational capabilities by 2019."

Orchard's pipeline includes transformative clinical and pre-clinical stage autologous, ex-vivo lentiviral gene therapies for primary immune deficiencies and inherited metabolic disorders. Its lead product, OTL-101, for the treatment of adenosine deaminase severe combined immunodeficiency (ADA-SCID) is in late-stage development and is anticipated to progress to a Biological License Application with the FDA in 2018. The OTL-101 development program has received a $19 million award from the California Institute for Regenerative Medicine (CIRM).





Subscribe

Subscribe



Newsbrief

FREE NEWSBRIEF SUBSCRIPTION

To receive the Scientist Live weekly email NewsBrief please enter your details below

Twitter Icon © Setform Limited
subscribe